Meredith Aldis is a reporter for FOX 7 Austin. She is from Cypress, Texas and graduated from Baylor University with a major in Journalism and a minor in Criminal Justice. While at Baylor, she was ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Wendyl Nissen and Paul Little have put their Hokianga property on the market and moved to Auckland. Photo / Jane Ussher Northland writers Wendyl Nissen and Paul Little have made the “bloody hard ...

PARKER — Meredith Barnhart has three state championship rings and a scholarship to Tennessee, but Lutheran’s insatiable slugging shortstop still insists on being best friends with her alarm.

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

with steel coil springs and conventional passive dampers. Nissan claims European versions of the car have had specific damper and steering tuning.

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...

In a 14-1 vote, the panel moved to expand its usage recommendation for both Pfizer’s Prevnar 20 and Merck’s Capvaxive to include all adults aged 50 and older as well as adults between 19 and ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).